新型抗血小板药物替格瑞洛与阿司匹林在脑梗死二级预防中的对比研究  

Comparative Study of Ticagrelor of Novel Antiplatelet Drug and Aspirin in Secondary Prevention of Cerebral Infarction

作　　者：杨伟 李萍 吴佑浩 范文峰[1] 王天仲 YANG Wei;LI Ping;WU Youhao;FAN Wenfeng;WANG Tianzhong(Department of Neurology,Zhongxiang People's Hospital,Zhongxiang 431900,China;不详)

机构地区：[1]钟祥市人民医院神经内科,湖北钟祥431900

出　　处：《中国医学创新》2025年第12期1-5,共5页Medical Innovation of China

摘　　要：目的:探讨新型抗血小板药物替格瑞洛与阿司匹林在脑梗死二级预防中的效果。方法:选取124例2020年3月-2022年1月钟祥市人民医院神经内科收治的脑梗死患者,按随机信封法分为试验组(n=62)、对照组(n=62)。对照组行阿司匹林治疗,试验组行新型抗血小板药物替格瑞洛治疗。对比两组认知与肢体功能、血小板聚集率、脑血流灌注参数、复发情况。结果:治疗6个月后,两组简易智力状态检查量表(MMSE)和Fugl-Meyer评估(FMA)得分均升高,1、5 min血小板聚集率均降低,且试验组MMSE和FMA得分均高于对照组,1、5 min血小板聚集率均低于对照组(P<0.05)。治疗6个月后,两组全脑血流量均增加,大脑中动脉(MCA)平均血流速度均增快,平均通过时间均缩短,且试验组全脑血流量大于对照组,MCA平均血流速度快于对照组,平均通过时间短于对照组(P<0.05)。试验组复发率为6.45%,低于对照组的19.35%(P<0.05)。结论:在脑梗死的二级预防中,替格瑞洛的疗效显著,可显著降低血小板聚集率,改善脑血流灌注,提高患者认知与肢体功能,并预防脑梗死复发。Objective:To explore the effect of Ticagrelor of novel antiplatelet drug and Aspirin in secondary prevention of cerebral infarction.Method:A total of 124 patients with cerebral infarction admitted to Department of Neurology,Zhongxiang People's Hospital from March 2020 to January 2022 were selected and divided into experimental group(n=62)and control group(n=62)according to random envelope method.The control group was treated with Aspirin,and the experimental group was treated with a novel antiplatelet drug of Ticagrelor.Cognition and limb function,platelet aggregation rate,cerebral blood perfusion parameters and recurrence were compared between the two groups.Result:After 6 months of treatment,the scores of mini-mental state examination(MMSE)and Fugl-Meyer assessment(FMA)increased in both groups,the platelet aggregation rate at 1 and 5 min decreased,and the scores of MMSE and FMA in the experimental group were higher than those in the control group,the platelet aggregation rate at 1 and 5 min were lower than those in control group(P<0.05).After 6 months of treatment,total cerebral blood flow increased,blood flow velocity of middle cerebral artery(MCA)accelerated and the average passage time shortened in both groups,and total cerebral blood flow in experimental group was greater than that in control group,blood flow velocity of MCA was faster than that in control group,and the average passage time was shorter than that in control group(P<0.05).The recurrence rate of experimental group was 6.45%,which was lower than 19.35%of control group(P<0.05).Conclusion:In secondary prevention of cerebral infarction,Ticagrelor has a significant effect,which can significantly reduce the platelet aggregation rate,improve cerebral blood perfusion,improve cognition and limb function of patients,and prevent cerebral infarction recurrence.

关 键 词：替格瑞洛 二级预防 阿司匹林 脑梗死 新型抗血小板药物 

分 类 号：R743.3[医药卫生—神经病学与精神病学]